In a recent study, the applicability of BEVs in cancer immunotherapy or cancer vaccines was reported showing that systemic intravenous administration of Gram-negative BEVs from the genetically modified Escherichia coli msbB–/– has a directed tropism for tumor site and a notably capability of inducing long-term antitumor immune responses through the secretion of CXCL10 and INFγ that can completely eradicate tumors without considerable adverse consequences (Kim et al., 2017). This evidence concerns the gene CXCL10 and cancer.